Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

Though we’ve recently observed some improvement in U.S. biosimilar penetration, market entry and uptake still consistently ...

Their discoveries have already led to the departure of a Stanford president, sparked charges from the Department of Justice, ...

AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...

TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Arthritis is a common acute or chronic condition affecting the joints and surrounding tissues. It’s estimated that roughly 18 ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

The story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...